CD28 Antibody (CD28.1): sc-19654
- CD28 Antibody (CD28.1) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against human CD28 Ig fusion protein and HPB-MLT human tumor cells
- recommended for detection of CD28 of human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for CD28 Antibody (CD28.1) for WB applications. These reagents are now offered in bundles with CD28 Antibody (CD28.1) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD28 Antibody (CD28.1) is a mouse monoclonal IgG1 antibody that detects CD28 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD28 plays a crucial role in T cell activation and proliferation by serving as a primary co-stimulatory receptor on T cells, which is essential for effective immune responses. Upon engagement with CD80 and CD86 ligands expressed on antigen-presenting cells, anti-CD28 antibody (CD28.1) enhances T cell activation and promotes cytokine production, thereby facilitating immune response against pathogens. CD28 signaling supports T cell survival and proliferation while helping T cell differentiation into effector and memory cells. The interaction of CD28 with ligands is critical for maintaining immune tolerance and preventing autoimmunity, making CD28 (CD28.1) monoclonal antibody a significant target for therapeutic interventions in various immune-related diseases. Anti-CD28 antibody (CD28.1) serves as an invaluable tool for researchers studying T cell biology and mechanisms underlying immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD28 Antibody (CD28.1) References:
- CD8+CD28- T cells: certainties and uncertainties of a prevalent human T-cell subset. | Arosa, FA. 2002. Immunol Cell Biol. 80: 1-13. PMID: 11869357
- CD28 and CTLA-4 coreceptor expression and signal transduction. | Rudd, CE., et al. 2009. Immunol Rev. 229: 12-26. PMID: 19426212
- CD3(+)CD8(+)CD28(-) T Lymphocytes in Patients with Lupus Nephritis. | Żabińska, M., et al. 2016. J Immunol Res. 2016: 1058165. PMID: 27446964
- CD8+CD28+ T cells might mediate injury of cardiomyocytes in acute myocardial infarction. | Zhang, L., et al. 2018. Mol Immunol. 101: 74-79. PMID: 29886399
- CD8+CD28- T cells: key cytotoxic players impacting disease pathogenesis in chronic HBV infection. | Nandi, M., et al. 2019. Clin Sci (Lond). 133: 1917-1934. PMID: 31477625
- Structural characterization of a dimerization interface in the CD28 transmembrane domain. | Wu, H., et al. 2022. Structure. 30: 803-812.e5. PMID: 35397202
- High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy. | Xu, X., et al. 2023. J Transl Med. 21: 64. PMID: 36721233
- CD28-signaling can be partially compensated in CD28-knockout mice but is essential for virus elimination in a murine model of multiple sclerosis. | Hülskötter, K., et al. 2023. Front Immunol. 14: 1105432. PMID: 37090733
- Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB. | De Sousa Linhares, A., et al. 2024. iScience. 27: 109267. PMID: 38455974
- CD28 signals through acidic sphingomyelinase. | Boucher, LM., et al. 1995. J Exp Med. 181: 2059-68. PMID: 7759998
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD28 Antibody (CD28.1) | sc-19654 | 200 µg/ml | $322.00 | |||
CD28 Antibody (CD28.1): m-IgG Fc BP-HRP Bundle | sc-538906 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD28 Antibody (CD28.1): m-IgG1 BP-HRP Bundle | sc-541139 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD28 Antibody (CD28.1) FITC | sc-19654 FITC | 200 µg/ml | $336.00 | |||
CD28 Antibody (CD28.1) PE | sc-19654 PE | 200 µg/ml | $349.00 |